Back to top
more

Thermo Fisher Scientific (TMO)

(Real Time Quote from BATS)

$598.75 USD

598.75
931,652

-16.94 (-2.75%)

Updated Aug 5, 2024 02:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Thermo Fisher Fundamentals Impressive Amid Tough Competition

Thermo Fisher (TMO) continues to gain considerable synergies from FEI acquisition. A raised guidance buoys optimism.

    Swarup Gupta headshot

    S&P 500 Nears 2,500: 5 Stock Picks for Big Profits

    The index has nearly always gained in the one-year period immediately following this winning streak.

      The Zacks Analyst Blog Highlights: Comcast, Thermo Fisher, China Life Insurance, Deere and American Airlines

      The Zacks Analyst Blog Highlights: Comcast, Thermo Fisher, China Life Insurance, Deere and American Airlines

        8 Factors That Make Thermo Fisher a Valuable Pick Right Now

        Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.

          Mark Vickery headshot

          Top Research Reports for Comcast, Thermo Fisher & China Life Insurance

          Today's Research Daily features new research reports on 16 major stocks, including Comcast (CMCSA), Thermo Fisher (TMO), and China Life Insurance (LFC).

            Thermo Fisher Acquires Patheon, Boosts Laboratory Products

            Thermo Fisher's (TMO) acquisition of Patheon significantly strengthens its Pharmaceutical and Biotech business by adding complementary services.

              Luminex Partners Sutter Health to Boost Molecular Testing

              The latest development is a significant addition to Luminex's (LMNX) molecular testing and diagnostic portfolio. The company has a broad product portfolio that comprises the advanced ARIES platform.

                Thermo Fisher (TMO) Up 1.9% Since Earnings Report: Can It Continue?

                Thermo Fisher (TMO) reported earnings about a month ago. What's next for the company? We take a look at earnings estimates for some clues.

                  Agilent (A) Sues Former Employees for Infringing IP Rights

                  Agilent Technologies has sued its former employees who formed Shanghai Echrom Electronic Technology Co.

                    Thermo Fisher's Patheon Buyout Gains Antitrust Clearance

                    Thermo Fisher (TMO) gets antitrust clearance to move a step closer toward completion of Patheon acquisition.

                      AmerisourceBergen (ABC) Q3 Earnings: Will It Disappoint?

                      AmerisourceBergen's (ABC) third-quarter performance face risks from reduced contract renewals and lower generic inflation.

                        Zimmer (ZBH) Tops Q2 Earnings, Drops View on Dull Sales

                        Zimmer Biomet's (ZBH) Q2 earnings results disappoint with an unimpressive Knee, Hip and Dental performances.

                          Boston Scientific (BSX) Tops Q2 Earnings & Sales, View Up

                          Boston Scientific's (BSX) Q2 results gain on balanced segmental growth. Currency remains a dampener though.

                            Thermo Fisher (TMO) Tops Q2 Earnings & Revenues, View Up

                            Thermo Fisher Scientific (TMO) continues to gain considerable synergies from FEI Company acquisition. A raised guidance buoys optimism.

                              Thermo Fisher (TMO) Beats on Q2 Earnings & Sales Estimates

                              Thermo Fisher (TMO) rides high in Q2 banking on its analytical instruments segment in particular.

                                Quest Diagnostics (DGX) Tops Q2 Earnings, Raises '17 View

                                Quest Diagnostics (DGX) continues to ride high on its advanced diagnostic offerings. Also, a raised view buoys optimism.

                                  Medical Instruments' Jul 26 Earnings Lineup: EW, TMO, VAR

                                  The ongoing political conflict resulting in a delay in policy implementation is a major dampener for Q2 earnings in the Medical space.

                                    Should You Buy Thermo Fisher Scientific Inc. (TMO) Ahead of Earnings?

                                    Thermo Fisher Scientific Inc. (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.

                                      Can Henry Schein (HSIC) Spring a Surprise in Q2 Earnings?

                                      The timing of Good Friday is likely to dampen sales at Henry Schein (HSIC) in second-quarter 2017. Meanwhile, geographic expansion should continue.

                                        What's in the Offing for Hologic (HOLX) in Q3 Earnings?

                                        Hologic's (HOLX) gain through product launch and Cynosure integration may get hampered by a dull Cytology performance.

                                          Can Illumina (ILMN) Spring a Surprise this Earnings Season?

                                          Illumina (ILMN) is well poised to witness steady top-line growth in Q2. Yet, the bottom line may remain stressed.

                                            What's in the Cards for DaVita (DVA) this Earnings Season?

                                            Despite a stable Kidney Care business, escalating expenses is likely to mar DaVita's (DVA) performance in the second quarter.

                                              Will Stryker (SYK) Deliver a Beat this Earnings Season?

                                              The growing adoption of Stryker's (SYK) MAKO robots is expected to drive second-quarter 2017 sales in the orthopedic and reconstructive surgery market.

                                                Is a Surprise in Store for ResMed (RMD) in Q4 Earnings?

                                                Currency headwind is likely to dampen ResMed's (RMD) gains in the COPD and sleep apnea market.

                                                  Boston Scientific (BSX) Q2 Earnings: What Awaits the Stock?

                                                  Lower TAVR sales due to recall of Lotus valves within the European and other key markets is likely to mar Boston Scientific's (BSX) top-line performance in Q2.